The management of financial conflict of interest (COI) in academic medicine has again been thrust in the spotlight,1 with some writers contending that current COI policies—largely a mandate to disclose conflicts, and, on rare occasion, recusal from academic opportunities or divestiture of the conflict—may perversely stifle biomedical innovation.2, 3, 4, 5 Others have argued in opposition, noting that loss of innovation is speculative, that historical breaches of trust led to current policies,...
